98%
921
2 minutes
20
Background: Bristol Myers Squibb (BMS), in collaboration with ZS and Tufts CSDD, recently conducted a detailed evaluation of participation burden associated with clinical outcome assessments, including patient reported outcomes.
Methods: A mixed-methods approach was used including an online global survey followed by in-depth interviews with patients and investigative sites to understand underlying causes of participation burden.
Results: 258 patients completed the online survey, 12 interviews were conducted among patients, and 12 interviews were conducted among investigative site personnel. The results show significant differences in patient perceptions of participation burden depending on the modalities and types of clinical outcome assessments administered in clinical trials. Specific modalities associated with elevated burden included those longer than 30 min and those completed several times per month. Perceived burden of clinical outcome assessments varied significantly by patient age and ethnicity. Investigative sites also reported the burden associated with administering electronic clinical outcome assessments - most notably the technical challenges and additional patient assistance required during initial setup, first patient visit, and technology management across different sponsors.
Conclusion: The results of this study raise clinical team and protocol author awareness of the patient participation burden associated with distinct types and modalities of clinical outcome assessments and informs decisions to selectively reduce this burden. The results of this study build on the Tufts CSDD-ZS Patient Burden Algorithm.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s43441-025-00832-9 | DOI Listing |
Vet Ophthalmol
September 2025
Ophthalmology Section, Equine Department, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Objective: To describe the use of transcorneal iris photocoagulation (TCIP) to improve intraocular visualization of intended incision lines, reduce hemorrhage, and facilitate excision of pigmented iridal tumors in four canine eyes and one feline eye.
Materials And Methods: A Rhodesian Ridgeback (treated bilaterally), a German Shepherd, a Labrador Retriever, and a Scottish Fold underwent sector iridectomy due to rapidly growing, pigmented, raised, iridal tumors affecting 1/4-1/3 of the iris circumference (3- to 4-clock hours). A diode laser was used to delineate the intended sector iridectomy incision lines, approximately 1-2 mm away from the grossly visible tumor margins, with the aim of improving visualization to achieve tumor-free margins and reduce tissue handling/trauma.
Arthritis Rheumatol
September 2025
Washington DC Veterans Affairs Medical Center; Georgetown University, Washington, DC, USA.
Objective: To evaluate the clinical characteristics, social deprivation, insurance coverage, and medication use across regional subsets of patients with psoriatic arthritis (PsA) in the US.
Methods: A cross-sectional study of PsA patients in the Rheumatology Informatics System for Effectiveness (RISE) registry between January 2020 and March2023 was conducted. Distribution of high disease activity (HDA - RAPID3>12), high comorbidity (RxRisk ≥90 percentile), high Area Deprivation Index (ADI ≥80), insurance coverage, prednisone ≥10mg daily, and all DMARD therapies across geographic regions were evaluated.
Haematologica
September 2025
Division of Hematology, Department of Medicine, The University of Colorado School of Medicine, Aurora CO 80045; Division of Hematology and Oncology, Department of Medicine, Rocky Mountain Regional VA, Aurora CO 80045.
Not available.
View Article and Find Full Text PDFHaematologica
September 2025
Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan; Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke.
Patient age might influence donor selection priorities in allogeneic hematopoietic stem cell transplantation (allo-HCT), due to the differences in donor age, organ function, and resistance to graft-versus-host disease between younger and older patients. We compared the transplant outcomes among human leukocyte antigen (HLA)-matched related donors (M-RDs, n=4,106), HLA 1-antigen-mismatched related donors (1MM-RDs, n=592), HLA 2-3-antigen-mismatched related donors (23MM-RDs, n=882), HLA-matched unrelated donors (M-UDs, n=3,927), HLA 1-locus-mismatched unrelated donors (1MM-UDs, n=2,474), and unrelated cord blood units (U-CBs, n=5,867) between patients aged.
View Article and Find Full Text PDF